Free Shipping On Orders Over $1,000!

SCRO Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Predicted Reactivity

  • Human
  • Mouse
  • Rat
  • Dog
  • Cow
  • Horse
  • Chicken
  • Rabbit
Overview
Catalog # bs-6523R-A350
Product Name SCRO Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Predicted Reactivity Human, Mouse, Rat, Dog, Cow, Horse, Chicken, Rabbit
Specifications
Conjugation ALEXA FLUOR® 350
Host Rabbit
Source KLH conjugated synthetic peptide derived from human SCRO/DCUN1D1
Immunogen Range 101-200/259
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 54165
Subcellular location Nucleus
Synonyms DCN1 defective in cullin neddylation 1 domain containing 1; DCN1 like protein 1; DCUN1 domain containing protein 1; DCUN1L1; Defective in cullin neddylation protein 1 like protein 1; RP 42; RP42; RP42 homolog; SCCRO; SCRO; Squamous cell carcinoma related oncogene; Tes 3; Tes3.
Background DCUN1D1 (DCUN1 domain-containing protein 1) contains a DUF298 domain and a UBA-like ubiquitin. Forms part of an E3 ubiquitin ligase complex for neddylation. Required for neddylation of cullin components of E3 cullin-RING ubiquitin ligase complexes by enhancing the rate of cullins neddylation. Functions to recruit the NEDD8-charged E2 enzyme to the cullin component. Involved in the release of inhibitory effets of CAND1 on cullin-RING ligase E3 complex assembly and activity. Acts also as an oncogene facilitating malignant transformation and carcinogenic progression. Defects in DCUN1D1 may be a cause of squamous cell carcinomas.Strongly overexpressed in thyroid tumors, bronchioloalveolar carcinomas, and malignant tissues of squamous cell carcinoma of the oral tongue. Not overexpressed in aggressive adrenocortical carcinomas.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200